FDA Authorizes First Pill Against COVID-19 as Omicron Cases Rise

Strategic Insights -

The US FDA has authorized the first pill against COVID-19, a Pfizer drug called Paxlovid, which can be taken at home to prevent severe symptoms. The move comes as cases, hospitalizations, and deaths are rising, with health officials warning of a potential tsunami of new infections from the Omicron variant. The drug, which has a nearly 90% reduction in hospitalizations and deaths, will be available in limited quantities initially, but its superiority in efficacy and mild side effects make it a preferred option.

Key Takeaways:

  • The FDA has authorized Pfizer's Paxlovid, a faster way to treat early COVID-19 infections, for adults and children ages 12 and older with a positive test and early symptoms who face the highest risks of hospitalization.
  • The drug is effective against Omicron because it doesn't target the spike protein where most of the variant's worrisome mutations reside.
  • The US government has agreed to purchase enough Paxlovid to treat 10 million people, with the option to provide it free to patients.
  • Pfizer currently has 180,000 treatment courses available worldwide, with approximately 60,000 to 70,000 allocated to the US, which will be rationed to the hardest hit areas.
  • The company says it can halve production time next year, with plans to produce 80 million courses globally under contracts with various countries.
  • The US will pay approximately $500 per course of treatment, which consists of three pills taken twice a day for five days.

Statistics:

  • The US is reporting over 140,000 new infections daily.
  • Approximately 40 million American adults remain unvaccinated.
  • Pfizer's Paxlovid has a nearly 90% reduction in hospitalizations and deaths among high-risk patients.
  • The FDA has authorized Paxlovid for adults and children ages 12 and older weighing at least 88 pounds.
  • The US government has agreed to purchase enough Paxlovid to treat 10 million people.

Sources:

  • The Associated Press
  • Matthew Perrone, The Associated Press
  • Dr. Gregory Poland, Mayo Clinic